Does brand + generic really add up? Sandoz, Actavis execs count the ways

Carly Helfand

These days, companies are increasingly looking to put both branded and meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' unit, doesn't know why they didn't do it sooner.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS